CTLA4 and neoplasm: Additionally, Jung et al. produced DEXs carrying both anti-cytotoxic T lymphocyte associated protein (CTLA)-4 antibodies and tumor antigens to improve the response rate of anti-CTLA-4 antibodies and reduce toxicity.